GRT-C901 for Carcinoma, Transitional Cell
This study is evaluating whether a personalized vaccine may help treat cancer.
See full descriptionAbout the trial for Carcinoma, Transitional Cell
Treatment Groups
This trial involves 2 different treatments. GRT-C901 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether GRT-C901 will improve 3 primary outcomes and 7 secondary outcomes in patients with Carcinoma, Transitional Cell. Measurement will happen over the course of Initiation of study treatment through 100 days post-last dose (up to approximately 27 months).
Patient Q & A Section
What are the signs of carcinoma, transitional cell?
The following signs are specific to transitional cell, urinary bladder cancer:\n- Blood or leukocytes in the urine\n- Pain in the back, or pain in the loins\n- Weight loss\n- Urine of a dark hue or tarry\n- Persistent and intense purging\n\nCarcinoma, transitional cell has a variable presentation. It can present either as a mass on the bladder, a change in urine characteristics or symptoms in a previously asymptomatic person.
What is carcinoma, transitional cell?
There have been a number of different names for a very similar entity but there remains much ambiguity and variation of terminology in this area. The name carcinoma, transitional cell is the appropriate one for a disease where differentiation between squamous epithelial cells and urothelial cells is present.
Can carcinoma, transitional cell be cured?
Radical cystectomy for carcinoma transitional cell or squamous cell of the urinary bladder is the recommended adjuvant therapeutic approach to patients with Stage T3N0M0 urothelial carcinoma. However, it can be used in select patient with Stage T2N0M0, T3N0M0 and T3N0M1 urothelial carcinoma.
What causes carcinoma, transitional cell?
The causation of carcinoma, transitional cell depends on genetics. It is likely for these diseases to be related and it is important to diagnose and treat any cancer in the urinary tract to avoid the risk of recurrence afterwards. Even with curative treatment, the recurrence of transitional cell carcinoma is common.
What are common treatments for carcinoma, transitional cell?
T1 and T2 are generally treated with surgery. A minority of the patients will have recurrent carcinoma, so the patients should be followed up regularly for surveillance.
How many people get carcinoma, transitional cell a year in the United States?
Nearly 500,000 people are diagnosed with transitional cell carcinoma of the bladder each year in the US. The overall 5-year survival rate in this disease is 67%; the median survival is 7 months. The survival rates for stage 0 and 1 bladder cancer were 62% and 55%, respectively.
Have there been other clinical trials involving grt-c901?
Oral grt-c901 is promising for use as a first line treatment for patients with metastatic papillary transitional cell carcinoma as the only objective indicator of improved survival in this population of patients is long term survival. Additional ongoing clinical trials are now needed for further evaluation of the potential clinical benefits of grt-c901. Clinicaltrials.gov number: NCT01093950.
Has grt-c901 proven to be more effective than a placebo?
Grt-c901 is safe and effective for the treatment of patients with advanced carcinoma of the larynx. Data from a recent study of this randomized and blinded trial, although encouraging overall, should be interpreted cautiously in view of the relatively small number of patients included, as well as the different ways in which the study was planned and carried out.
What is grt-c901?
The grt-c901 is an exciting new cancer treatment compound that may be capable of controlling cancers at a very low dosage. Proteins for Cancer Research, 4(3): 277–280, 2004(4). [Power(http://www.withpower.
What is the primary cause of carcinoma, transitional cell?
Carcinoma, transitional cell predominates as the initial diagnosis (51%). It is recommended that the diagnosis is established on a combination of cystoscopy and pathological examination of the urine for malignant cells.
What is the average age someone gets carcinoma, transitional cell?
This was not a large sample, and it may not necessarily reflect true incidence patterns, but the data can nonetheless provide insight into the incidence and prevalence of the disease to the medical community.
Does grt-c901 improve quality of life for those with carcinoma, transitional cell?
In a recent study, findings of the current study suggest that the combination of grt-c901 and trichostatin A may be a well-tolerated and effective therapy for metastatic transitional cell carcinoma.